

Johnson & Johnson launches platform to advance atrial fibrillation treatment across Asia-Pacific

08 July 2025 | News

The VARIPULSE™ Platform is approved in Japan, Hong Kong, China, Australia, Taiwan and Korea.



Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, has launched VARIPULSE™ Platform in Asia-Pacific to perform Cardiovascular Solutions.

The VARIPULSE™ Platform is Johnson & Johnson MedTech's Pulsed Field ablation system. The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency, reproducibility, and procedural accuracy. The VARIPULSE™ Platform is approved in Japan, Hong Kong, China, Australia, Taiwan and Korea in Asia Pacific. With this Platform is now approved for use in the United States, Europe, Asia Pacific, and Canada.

Catheter ablation procedures for atrial fibrillation (AFib), an irregular and often rapid heartbeat caused by extra, uncoordinated electrical signals in the atria will be performed by using this platform. AFib is associated with structural changes in the heart due to underlying conditions and lifestyle factors. It significantly increases the risk of stroke, heart failure, and mortality.

The VARIPULSE™ Platform is the first PFA technology designed to streamline ablation and mapping through a single integrated workflow with the CARTO™ 3 System. This 3D electroanatomical cardiac mapping technology enables real-time visualization and supports precision, efficiency, reproducibility, and procedural accuracy for physicians treating patients with atrial fibrillation (AFib). It enables safe and efficient patient-centric therapy with minimal to no fluoroscopy exposure and is compatible with deep and/or conscious sedation.

Jing Li, Vice President, Electrophysiology & Neurovascular, Johnson & Johnson MedTech, Asia Pacific said "The adoption of the VARIPULSE™ Platform could demonstrate the unique value of integration with CARTO™ 3D to enhance efficiencies in the workflow of AFib treatment and improve patient outcomes."